Late-Breaking Clinical Trials (LBCT) debuted at HRX Live 2026 as an inaugural program.
Presentations featured First-in-Human and Early Feasibility studies at the moment they begin to influence thinking, discussion, and decision-making across electrophysiology and cardiovascular innovation.
Presented live on the HRX Main Stage, the inaugural LBCT session brought early clinical evidence into a collaborative, cross-disciplinary environment, connecting emerging data with the clinicians, researchers, industry leaders, and innovators shaping what comes next.
LBCT presentations focus on First-in-Human studies, including new data not previously presented at any another conference.
Late-Breaking Clinical Trials at HRX Live are designed to:
Presenting Late Breaking Clinical Trials at HRX Live offers a unique opportunity to:
Share early clinical evidence in a high-trust, collaborative setting
Engage directly with clinicians, industry leaders, and innovators
Receive real-time feedback and perspective beyond traditional scientific formats
Participate in conversations that influence adoption, integration, and next-step development
Only a select number of submissions will be chosen for Main Stage presentation. The cost to submit each LBCT is $175 for HRS members and $275 for non-members. Additional submission details and guidelines will are available in the Submission Guidelines.
Accepted LBCTs will be:
Presented on the Main Stage at HRX Live 2026
Published in Heart Rhythm O²